Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Nexalin Technology, Inc. - Common Stock (NQ:NXL)

0.3500 -0.0175 (-4.76%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 8, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	55,862
Open	0.3750
Bid (Size)	0.3501 (300)
Ask (Size)	0.3704 (100)
Prev. Close	0.3675
Today's Range	0.3500 - 0.3750
52wk Range	0.3401 - 2.310
Shares Outstanding	N/A
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor Conference

April 02, 2026

Via ACCESS Newswire

Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market

February 24, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Performance

YTD	-39.9%	-39.9%
1 Month	-23.1%	-23.1%
3 Month	-54.1%	-54.1%
6 Month	-62.7%	-62.7%
1 Year	-78.8%	-78.8%

More News

Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders

February 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

February 13, 2026

Via ACCESS Newswire

Unusual volume stocks in Friday's session ↗

February 06, 2026

Via Chartmill

Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care

February 05, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Discover the top movers in Thursday's pre-market session. ↗

February 05, 2026

Via Chartmill

Top movers in Tuesday's pre-market session ↗

February 03, 2026

Via Chartmill

Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation

February 02, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Receives Nasdaq Listing Status Notification

January 23, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Published Peer-Reviewed Study Demonstrates Nexalin’s DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD

January 14, 2026

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer’s Disease Program

December 03, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on December 4

December 02, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Wondering what's happening in today's pre-market session? ↗

November 19, 2025

Via Chartmill

Nexalin’s 15 Milliamp Neurostimulation Device Demonstrates Promising Results in Treating Gambling Disorder with Alcohol Use Comorbidity

November 18, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Appoints Carmi Masha Technologies Ltd. as Exclusive Distributor in Israel

November 13, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology’s Q-Submission for Gen-2 SYNC Accepted by U.S. FDA for the Treatment of Alzheimer’s Disease and Dementia

November 05, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Regulatory Approval to Sell Gen 2 SYNC, 15 mA Neurostimulation DIFS™ Device in Israel

October 30, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin’s DIFS™ Neurostimulation Shows Cognitive and Brain Network Improvements in Alzheimer’s and Dementia Across Three Peer-Reviewed Studies

October 21, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology and BioVie Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

October 17, 2025

Via ACCESS Newswire

Nexalin Technology Expands Scientific Advisory Board with Appointment of Dr. Robert Rothstein to Support Alzheimer’s and Traumatic Brain Injury Programs

October 13, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

Nexalin Technology Announces Attendance at the 2025 Maxim Growth Summit

October 10, 2025

From Nexalin Technology, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

October 09, 2025

Via Benzinga

Gapping stocks in Thursday's session ↗

October 09, 2025

Via Chartmill

Which stocks are moving before the opening bell on Thursday? ↗

October 09, 2025

Via Chartmill

Frequently Asked Questions

Is Nexalin Technology, Inc. - Common Stock publicly traded?

Yes, Nexalin Technology, Inc. - Common Stock is publicly traded.

What exchange does Nexalin Technology, Inc. - Common Stock trade on?

Nexalin Technology, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Nexalin Technology, Inc. - Common Stock?

The ticker symbol for Nexalin Technology, Inc. - Common Stock is NXL on the Nasdaq Stock Market

What is the current price of Nexalin Technology, Inc. - Common Stock?

The current price of Nexalin Technology, Inc. - Common Stock is 0.3500

When was Nexalin Technology, Inc. - Common Stock last traded?

The last trade of Nexalin Technology, Inc. - Common Stock was at 04/08/26 04:00 PM ET

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433